Danny Bega, MD
Neurology · Chicago, ILNPI 1619104148
Payments from drug & device makers
Across 498 payments — averaging $5637.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.3M
- Neurocrine Biosciences, Inc.$326K
- Sage Therapeutics, LLC$293K
- AstraZeneca$205K
- Ultragenyx Pharmaceutical Inc.$178K
- Biogen$148K
- plus $362K from 18 others
Across 5 payments — averaging $2030.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$10K
What the payments were for
- Consulting fees$98,86722%
- Speaking & faculty fees$317,19972%
- Travel & lodging$15,7704%
- Food & beverage$8,1332%
- Education$1,7790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 61 | $1,294,812 |
| Neurocrine Biosciences, Inc. | 108 | $326,445 |
| Sage Therapeutics, LLC | 11 | $292,839 |
| AstraZeneca | 18 | $205,289 |
| Ultragenyx Pharmaceutical Inc. | 33 | $178,137 |
| Biogen | 7 | $148,106 |
| Teva Pharmaceuticals USA, Inc. | 79 | $133,815 |
| Acorda Therapeutics, Inc | 53 | $73,015 |
| Roche TCRC, Inc. | 13 | $43,505 |
| AbbVie(2 entities) | 36 | $30,683 |
| Kyowa Kirin, Inc. | 21 | $25,357 |
| MDD US Operations, LLC | 18 | $19,418 |
| Adamas Pharmaceuticals, Inc. | 7 | $6,780 |
| Amneal Pharmaceuticals LLC | 8 | $6,634 |
| Sunovion Pharmaceuticals Inc. | 5 | $6,375 |
| GE HealthCare | 6 | $4,852 |
| Orphalan Inc | 4 | $3,661 |
| Acadia Pharmaceuticals Inc | 2 | $2,950 |
| Novartis | 2 | $2,914 |
| Sumitomo Pharma America, Inc. | 1 | $625 |
| Genentech USA, Inc. | 2 | $601 |
| Vertex | 1 | $420 |
| PTC Therapeutics, Inc. | 1 | $233 |
| Boston Scientific | 1 | $185 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,807,650 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 82 | $625,258 |
| NuplazidPimavanserin Tartrate | 74 | $472,258 |
| AustedoDeutetrabenazine | 29 | $365,133 |
| GocovriAmantadine Hcl | 111 | $255,476 |
| RytaryCarbidopa/Levodopa | 86 | $254,333 |
| InbrijaLevodopa | 33 | $122,752 |
| Austedo XrDeutetrabenazine | 11 | $77,072 |
| Tetrabenazine | 17 | $33,549 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 601 | $23,755 |
| CrexontCarbidopa/Levodopa | 11 | $21,272 |
| Droxidopa | 15 | $13,341 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,483 |
| AmantadineAmantadine Hcl | 163 | $10,319 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 294 | $9,646 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 19 | $7,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $326,445 | $625,25882 claims |
| Acadia Pharmaceuticals IncNuplazid | $2,950 | $472,25874 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $133,815 | $442,20640 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $6,634 | $275,60597 claims |
| MDD US Operations, LLCGocovri | $19,418 | $255,476111 claims |
| Acorda Therapeutics, IncInbrija | $73,015 | $122,75233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Chicago
- Tatyana SimuniChicago$3.5M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Dusan StefoskiChicago$1.5M
- Kourosh RezaniaChicago$1.4M
- Adil JavedChicago$1.4M
- Deborah HallChicago$1.4M
- Thomas ShoemakerChicago$1.2M
- Neelum AggarwalChicago$944K
- Tao XieChicago$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.